Cas:102624-96-4 Azetidine-3-carboxylic acid��HCl manufacturer & supplier

Chemical Name:Azetidine-3-carboxylic acid��HCl

CAS.NO:102624-96-4

Synonyms:3-Azetidinecarboxylic acid, hydrochloride (1:1);3-Azetidinecarboxylic acid hydrochloride (1:1);Azetidine-3-carboxylic acid��HCl;Azetidine-3-carboxylic acid hydrochloride (1:1);azetidine-3-carboxylic acid,hydrochloride

Molecular Formula:C₄H₈ClNO₂

Molecular Weight:137.565

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:268.5ºC at 760mmHg

Density:N/A

Index of Refraction:

PSA:49.33000

Exact Mass:137.024353

LogP:0.42120

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Azetidinecarboxylic acid, hydrochloride (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,azetidine-3-carboxylic acid,hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Azetidine-3-carboxylic acid hydrochloride (1:1) Use and application,3-Azetidinecarboxylic acid, hydrochloride (1:1) technical grade,usp/ep/jp grade.

Related News: Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. Azetidine-3-carboxylic acid��HCl manufacturer Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. Azetidine-3-carboxylic acid��HCl supplier What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. Azetidine-3-carboxylic acid��HCl vendor The term active pharmaceutical ingredient may refer to an active chemical within an FDA-regulated drug, or API might mean the entire drug with its active and inactive ingredients. Azetidine-3-carboxylic acid��HCl factory Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost.